Products

TAVIPILOT
Carvolix
Cardiology AI
TAVIPILOT Soft by Caranx Medical is an FDA-cleared AI software providing real-time guidance for Transcatheter Aortic Valve Implantation (TAVI/TAVR), enhancing precision and democratizing access to life-saving procedures.

See all 1 product →

About Carvolix

Carvolix is a French MedTech company that specializes in the development of AI-driven mini-robots and biomimetic implants, aiming to revolutionize interventional cardiology and the treatment of ischemic stroke. The company’s mission is to democratize complex, life-saving procedures by empowering interventional cardiologists with AI-guided mini-robotic technologies. These technologies are designed to support clinicians during the most technically demanding steps of heart and stroke interventions, with the goal of improving procedural efficiency, safety, and patient outcomes.

Carvolix’s platform enables a broader base of physicians to perform complex interventions with greater precision, confidence, and reproducibility, ultimately accelerating patient access to life-saving therapies. The company’s portfolio includes the TAVIPILOT platform for transcatheter aortic valve implantation (TAVI), which consists of both software and a robotic component, as well as solutions for mitral valve repair and replacement, and autonomous robotic solutions for stroke treatments. Carvolix aims to address the significant unmet medical needs in structural heart disease and ischemic stroke, where currently only a small percentage of eligible patients receive treatment.

Focus Areas

AI-driven surgical robotics transcatheter aortic valve implantation (TAVI) cardiovascular therapies stroke treatment real-time intraoperative guidance medical imaging autonomous mini-robots biomimetic implants

Business Intelligence

TechnologyAI-driven autonomous mini-robots, real-time intraoperative guidance software, machine learning based on patient records and video recorded operations, cloud-connected systems (for future expansion)

What Physicians Need to Know

AI-Driven Surgical Robotics
Carvolix specializes in AI-driven mini-robotics for complex cardiac and brain stroke interventions, aiming to democratize access to life-saving procedures. Their mini-robots operate with supervised autonomy, guided by real-time imaging and artificial intelligence.
Transcatheter Aortic Valve Implantation (TAVI)
Carvolix's TAVIPILOT platform, including TAVIPILOT Software and TAVIPILOT Robot, provides AI-driven real-time intraoperative guidance for precise valve positioning during TAVI procedures. The TAVIPILOT Software received FDA clearance in July 2025 and is commercially available in the US. The TAVIPILOT Robot is currently under clinical development with FDA submission in September 2026, targeting a US launch of the integrated platform in early 2027.
Cardiovascular Therapies
Beyond TAVI, Carvolix is developing solutions for other structural heart diseases, including mitral insufficiency with their MITRA-PILOT platform and Kalios™ adjustable mitral annuloplasty device. They also have the Epygon biomimetic transcatheter mitral valve, designed to restore natural blood flow.
Stroke Treatment
Carvolix's ARTEDRONE solution focuses on ischemic stroke treatment, utilizing autonomous mini-robots and magnetic-guided catheters to expand access to mechanical thrombectomy.
Real-time Intraoperative Guidance & Medical Imaging
Their AI-powered software, like TAVIPILOT Software, offers continuous visualization of anatomical landmarks and prosthetic valves, providing real-time guidance and depth assessment during procedures. This technology is compatible with all cardiac imaging systems.
Autonomous Mini-Robots
Carvolix's core innovation lies in its AI- and imaging-driven mini-robotic technologies, designed to assist with navigation and positioning in complex interventions, aiming for supervised autonomy.
Biomimetic Implants
Carvolix develops innovative biomimetic implants, such as the Epygon transcatheter mitral valve, which mimics the anatomy of the native mitral valve to restore natural blood flow and foster ventricular function recovery.
Physician Tip

Carvolix's technologies, such as the TAVIPILOT platform, are designed to enhance precision, consistency, and speed in complex procedures like TAVI, potentially improving procedural efficiency, safety, and patient outcomes. The AI-driven guidance aims to empower interventional cardiologists, including those in smaller centers or with less experience, to perform complex interventions with greater confidence and reproducibility, thereby expanding patient access to advanced therapies. The TAVIPILOT Software has shown promising results in clinical studies, including 100% procedural success and observed reductions in procedure duration, fluoroscopy time, and contrast agent usage. The Kalios™ adjustable mitral ring offers a new paradigm for mitral repair by allowing percutaneous adjustment on a beating heart, potentially avoiding repeat open-heart surgery for many patients.

Carvolix's TAVIPILOT Software is designed to be compatible with all cardiac imaging systems and will be compatible with all TAVI heart valves on the market. This broad compatibility suggests a focus on seamless integration into existing cath lab workflows and with various commercially available devices.

Products by Carvolix

1 product in the directory

TAVIPILOT
Carvolix
Cardiology AI
TAVIPILOT Soft by Caranx Medical is an FDA-cleared AI software providing real-time guidance for Transcatheter Aortic Valve Implantation (TAVI/TAVR), enhancing precision and democratizing access to life-saving procedures.

What the Web Says

Carvolix (Caranx Medical) is a company focused on medical devices, specifically in the field of robotics for interventional cardiology. While direct product reviews for 'Carvolix' or 'Caranx Medical' on major review platforms like G2, Glassdoor, Capterra, or Reddit are scarce, their work appears to be in a specialized and innovative area within healthcare technology. Information regarding employer reviews is also not readily available on common platforms.

Overall: Mixed

Strengths

  • Focus on innovative medical robotics
  • Potential to improve interventional cardiology procedures
  • Specialized niche in healthcare technology

Limitations

  • Limited public reviews or detailed product information
  • Scarcity of employer reviews on major platforms
  • Specific product details and user experiences are not easily found
  • Unknown market adoption or clinical trial results from public sources

Based on reviews from: Caranx Medical Website, General web search (G2, Glassdoor, Capterra, Reddit, healthcare IT reviewer searches yielded no specific results for 'Carvolix' or 'Caranx Medical' reviews)

Last updated: 2026-10-19

Videos

News, demos, and interviews about Carvolix.

Loading videos...

Videos load interactively. If none appear, search YouTube for Carvolix →

View all on YouTube

Press & Coverage

Pharmafile
New medtech company Carvolix created as Affluent Medical acquires Caranx Medical and Artedrone
Carvolix, formerly Affluent Medical, was formed through the acquisition of Caranx Medical and Artedrone, aiming to use AI-powered mini-robots and biomimetic implants to improve access to life-saving cardiac valve replacement and stroke procedures. The company expects to launch its first product, TAVIPILOT Software, in the US in 2026, following FDA approval.
2026-02
Invest in Côte d'Azur
Caranx Medical, a Nice-based cardiac robotics MedTech startup, set to be acquired for €16.6 million
Caranx Medical, along with Artedrone, is set to be acquired by Affluent Medical for €16.6 million and combined into a new MedTech entity named Carvolix, with completion scheduled for January 30, 2026. Caranx Medical's TAVIPILOT Soft, the world's first AI software authorized by the FDA for real-time intraoperative guidance of transcatheter heart valve implantation, is planned for commercialization in the US in early 2026.
2026-01
Patient Daily
Carvolix secures €30 million investment from Claret Capital Partners for MedTech expansion
Carvolix, formerly Affluent Medical, secured a €30 million investment from Claret Capital Partners to accelerate the commercialization of its MedTech portfolio, focusing on AI-driven mini-robots and biomimetic implants for interventional cardiology and ischemic stroke treatment. The funding will support the commercialization of its lead product, TAVIpilot, designed to assist interventional cardiologists during complex procedures.
2026-08
Carvolix (EQS News)
Carvolix submits 510(k) for TAVIPILOT Robot, advancing toward US commercial launch of Its Integrated TAVIPILOT Platform.
Carvolix submitted a 510(k) application to the FDA for its TAVIPILOT Robot, a key regulatory step for the planned US launch of its integrated TAVIPILOT platform in early 2027. The TAVIPILOT Robot is designed to assist with the navigation and positioning of transcatheter heart valves, complementing the FDA-cleared TAVIPILOT Software.
2026-09
Business Wire
Caranx Medical Announces First Clinical Use of the TAVIPILOT Soft, Cleared by FDA for Commercial in July: the World First AI Software for Real-Time Intra-Operative Guidance of Transcatheter Heart Valve Implantation
Caranx Medical announced the first clinical use of its FDA-cleared TAVIPILOT Soft platform for robotic transcatheter aortic valve implantation (TAVI) in October 2025, confirming its potential for real-time guidance to enhance precision and improve patient outcomes. The company aims for early commercialization in the US by the end of 2025.
2025-11
Dealroom News
Carvolix (formerly Affluent Medical) secures new €10M tranche, bringing total financing to €20M
Carvolix secured a new €10 million tranche, bringing its total financing to €20 million within a €30 million program, with funds primarily allocated to product development, including the TAVIPILOT robot. This funding, from existing shareholders including Edwards Lifesciences and Truffle Capital, is crucial for the company's regulatory milestones, such as FDA clearance for its TAVIPILOT robot.
2026-06
Cardiovascular Business
FDA clears AI-powered software for real-time TAVR guidance
Caranx Medical received FDA clearance for TAVIPILOT Soft, its AI-powered software providing real-time guidance during transcatheter aortic valve replacement (TAVR) procedures, making it the first FDA-cleared software of its kind. This software is designed to expand patient access to life-saving procedures by assisting cardiologists with precise and accurate heart valve positioning.
2025-07
Carvolix
Carvolix presents promising clinical data on the TAVIPILOT platform at New York Valves 2026
Carvolix presented detailed clinical results for both its TAVIPILOT AI software and the TAVIPILOT Robot at New York Valves 2026, showcasing promising insights with observed reductions in procedure duration, fluoroscopy time, and contrast agent usage. The TAVIPILOT Robot, the world's first AI-driven robotic platform for TAVI, demonstrated 100% procedural success with no device-related safety events in its first-in-human clinical experience.
2026-07

Frequently Asked Questions

Carvolix specializes in AI-driven surgical robotics designed to augment precision in complex cardiovascular interventions. Our platforms integrate real-time intraoperative guidance with advanced imaging, aiming to optimize procedural accuracy and improve patient outcomes in procedures like Transcatheter Aortic Valve Implantation (TAVI).
Carvolix adheres to stringent regulatory frameworks for all its medical devices, including autonomous mini-robots and biomimetic implants. We prioritize patient safety through rigorous testing, clinical validation, and continuous monitoring, ensuring full compliance with global healthcare regulations for stroke treatment and cardiovascular therapies.
Carvolix offers flexible pricing models for our AI-driven surgical systems and cardiovascular therapy products, which can include outright purchase, lease options, or per-procedure agreements. Our comprehensive support packages typically encompass installation, training, ongoing technical assistance, and regular software updates to ensure optimal performance.
Carvolix actively collaborates with several prominent medical institutions and research centers globally. These partnerships are crucial for the co-development, clinical validation, and continuous innovation of our real-time intraoperative guidance and advanced medical imaging technologies, ensuring they meet the evolving needs of healthcare professionals.
Carvolix is committed to being a leader in AI-driven healthcare innovation, with a robust long-term vision focused on expanding our portfolio in autonomous mini-robots and biomimetic implants. Our company stability is underpinned by strong investment, a clear strategic roadmap, and a dedication to continuous research and development to address future medical challenges.

Related Companies

Surgical Reality is a healthcare AI company that specializes in advanced AI-powered 3D medical imaging and surgical planning software for thoracic surgery. Their core product, the Surgical Reality Viewer, converts standard CT scans into high-fidelity, patient-specific 3D models of the entire lung within minutes. This technology is designed to assist trained healthcare professionals with preoperative […]

Meril Life Sciences is an Indian multinational medical device company dedicated to the innovation, design, and development of clinically relevant and state-of-the-art devices. The company focuses on alleviating human suffering and improving the quality of life through advanced healthcare solutions. Meril’s extensive product portfolio spans various medical fields, including vascular intervention, orthopedic implants, robotics, endosurgery, […]

Caption Health, formerly known as Bay Labs and now part of GE HealthCare, is a pioneering medical artificial intelligence (AI) company dedicated to expanding access to high-quality ultrasound examinations. The company’s core offering is the Caption AI platform, which utilizes AI to guide healthcare providers, including those without extensive specialized training, in acquiring and interpreting […]

Anumana is an AI-driven health technology company dedicated to transforming cardiovascular care. Co-founded by nference and Mayo Clinic, Anumana develops software-as-a-medical-device (SaMD) solutions that leverage multimodal AI to support early detection, clinical decision-making, and intraoperative guidance across the continuum of care. The company’s portfolio includes FDA-cleared ECG-based algorithms, generative imaging applications, and real-time procedural support […]

Keya Medical Technology Co. is an international medical technology company specializing in deep learning-based AI solutions for non-invasive disease diagnosis and treatment. The company, founded in 2016, develops AI-enabled diagnostic devices that aim to enhance efficiency, accuracy, and precision in healthcare across various specialties, including cardiology, neurology, pulmonology, pathology, and surgery. [2, 4, 8, 14] […]

Siemens Medical Solutions USA, Inc., operating as Siemens Healthineers USA, is a prominent medical technology company with a rich history spanning over 175 years, dedicated to pioneering breakthroughs in healthcare. As a subsidiary of the global Siemens Healthineers AG, the company offers a comprehensive portfolio that is central to clinical decision-making across the entire healthcare […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.